Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

COURTNEY D ACKERMAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1790919744
CMS profile
585146
Location
SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,292.42

150 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,275.44 137
Long term medical supply or device loan $999.96 12
Education $17.02 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $1,344.13 26
Janssen Biotech, Inc. $406.75 17
AstraZeneca Pharmaceuticals LP $209.64 8
ABBVIE INC. $175.89 6
Daiichi Sankyo Inc. $164.56 7
PFIZER INC. $153.81 7
Regeneron Healthcare Solutions, Inc. $118.23 6
GlaxoSmithKline, LLC. $95.59 4
Merck Sharp & Dohme LLC $84.68 5
Aveo Pharmaceuticals, Inc. $80.04 2
Agios Pharmaceuticals, Inc. $71.35 3
Eisai Inc. $70.52 3
Kite Pharma, Inc. $69.89 3
Incyte Corporation $68.53 3
Genmab U.S., Inc. $67.96 2
Pharmacosmos Therapeutics Inc. $63.09 3
Mirati Therapeutics, Inc. $61.68 2
Boston Scientific Corporation $59.70 2
Karyopharm Therapeutics Inc. $58.28 2
Dendreon Pharmaceuticals LLC $56.70 2
BeiGene USA, Inc. $53.83 2
PharmaEssentia USA Corporation $52.94 2
ADC Therapeutics America, Inc. $49.25 2
SHIELD THERAPEUTICS INC $48.63 2
Takeda Pharmaceuticals U.S.A., Inc. $44.82 2
Genentech USA, Inc. $39.66 2
PUMA BIOTECHNOLOGY, INC. $38.19 2
Astellas Pharma US Inc $34.80 1
Sumitomo Pharma America, Inc. $31.94 2
Ipsen Biopharmaceuticals, Inc $29.66 1
Bayer Healthcare Pharmaceuticals Inc. $29.55 1
Alexion Pharmaceuticals, Inc. $28.53 1
Celgene Corporation $26.55 1
Invivyd Inc $23.64 1
SpringWorks Therapeutics, Inc. $23.24 1
Spectrum Pharmaceuticals Inc. $21.96 1
Rigel Pharmaceuticals, Inc. $21.75 1
GENZYME CORPORATION $21.33 1
SOBI, INC $20.60 1
Lilly USA, LLC $20.51 1
TAIHO ONCOLOGY, INC. $19.87 1
Exelixis Inc. $19.56 1
Kyowa Kirin, Inc. $18.65 1
SERVIER PHARMACEUTICALS LLC $18.46 1
ARRAY BIOPHARMA INC $17.72 1
Amgen Inc. $15.60 1
Deciphera Pharmaceuticals Inc. $14.07 1
Alnylam Pharmaceuticals Inc. $13.24 1
Janssen Pharmaceuticals, Inc $12.85 1

Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

COURTNEY D ACKERMAN

NPI 1790919744 · CMS profile ID 585146

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790919744?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
COURTNEY D ACKERMAN, NPI 1790919744, CMS profile ID 585146. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790919744?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). COURTNEY D ACKERMAN, NPI 1790919744, CMS profile ID 585146. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790919744?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
COURTNEY D ACKERMAN, NPI 1790919744, CMS profile ID 585146, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1790919744?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

150 matching records · $4,292.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 150 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 150.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $15.6008/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111509079 CMS
Janssen Biotech, Inc. $12.8108/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078587089 CMS
Novartis Pharmaceuticals Corporation $34.7808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086730217 CMS
Daiichi Sankyo Inc. $29.9908/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089390842 CMS
ABBVIE INC. $44.9308/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103171728 CMS
TAIHO ONCOLOGY, INC. $19.8708/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137937009 CMS
Exelixis Inc. $19.5608/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138556553 CMS
Novartis Pharmaceuticals Corporation $83.3308/23/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086730219 CMS
Regeneron Healthcare Solutions, Inc. $32.4308/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994155 CMS
BeiGene USA, Inc. $18.9908/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120856679 CMS
Alexion Pharmaceuticals, Inc. $28.5308/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093998941 CMS
Genmab U.S., Inc. $34.1108/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126825535 CMS
ADC Therapeutics America, Inc. $24.2808/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121193403 CMS
Spectrum Pharmaceuticals Inc. $21.9607/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150655089 CMS
Kite Pharma, Inc. $24.8607/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1128610395 CMS
Ipsen Biopharmaceuticals, Inc $29.6607/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091963459 CMS
Janssen Biotech, Inc. $12.6207/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078588841 CMS
GENZYME CORPORATION $21.3307/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139807619 CMS
Karyopharm Therapeutics Inc. $31.9407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145528636 CMS
GlaxoSmithKline, LLC. $30.6407/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115985253 CMS
Genentech USA, Inc. $21.5807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132991840 CMS
Novartis Pharmaceuticals Corporation $83.3307/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086730235 CMS
AstraZeneca Pharmaceuticals LP $32.2507/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105871387 CMS
Janssen Biotech, Inc. $9.9607/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078587668 CMS
Boston Scientific Corporation $40.6607/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092321387 CMS
Regeneron Healthcare Solutions, Inc. $14.9907/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994153 CMS
SHIELD THERAPEUTICS INC $20.1707/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150136917 CMS
Eisai Inc. $22.5207/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110737749 CMS
Aveo Pharmaceuticals, Inc. $44.0907/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143475532 CMS
Merck Sharp & Dohme LLC $16.6106/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141823011 CMS
ABBVIE INC. $34.1906/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103171726 CMS
Janssen Biotech, Inc. $12.4806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078582104 CMS
Janssen Biotech, Inc. $38.9306/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078587501 CMS
AstraZeneca Pharmaceuticals LP $26.7706/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104295480 CMS
PUMA BIOTECHNOLOGY, INC. $14.1506/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113844167 CMS
Rigel Pharmaceuticals, Inc. $21.7506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145204884 CMS
Boston Scientific Corporation $19.0406/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092321385 CMS
AstraZeneca Pharmaceuticals LP $24.0806/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104344754 CMS
Novartis Pharmaceuticals Corporation $83.3306/13/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086730233 CMS
Janssen Biotech, Inc. $68.5006/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078586121 CMS
Janssen Biotech, Inc. $9.3806/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078586142 CMS
Novartis Pharmaceuticals Corporation $21.2406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086730215 CMS
AstraZeneca Pharmaceuticals LP $26.7206/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105254303 CMS
SOBI, INC $20.6006/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141422717 CMS
PFIZER INC. $28.6805/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131326574 CMS
Dendreon Pharmaceuticals LLC $24.3305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149311808 CMS
Daiichi Sankyo Inc. $23.4705/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089390840 CMS
Janssen Biotech, Inc. $20.6605/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078583708 CMS
Novartis Pharmaceuticals Corporation $83.3305/16/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086730231 CMS
Agios Pharmaceuticals, Inc. $22.9905/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149643138 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,342.26 116
PY2020 $2,737.59 158
PY2021 $4,287.39 180
PY2022 $3,993.01 184
PY2023 $2,984.72 127
PY2024 $4,292.42 150
PY2025 $3,884.03 134

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $403,699.59 7
PY2024 Principal investigator $95,481.89 6
PY2023 Principal investigator $416,595.81 7
PY2022 Principal investigator $308,563.37 11
PY2021 Principal investigator $5,100.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

7 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,041.97 12/31/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with BRCA1,BRCA2,or PALB2 mutations and hormone receptor positive, HER2 negative IHC 0,1+,2+ISH non-amplified advanced breast cancer evoPAR breast01 No dispute reported 06/30/2026 1185555971
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,009.78 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185555965
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,244.49 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185555973
Principal investigator 1 AstraZeneca Pharmaceuticals LP $358,408.75 01/29/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185555969
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,635.40 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185555963
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,566.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185555967
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,793.20 01/10/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185555975